AscellaHealth is 1 of 26 Philadelphia-area firms on Inc.’s List of Fastest-Growing Northeast Companies

AscellaHealth Ranks No. 48 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies

AscellaHealth Launches Biopharmaceutical Educational Podcast Series

Specialty Drug Tiering, Indication Expansions, IRA Are Some Issues to Watch

Humira Is Not Only Specialty Drug With Anticipated Biosimilars

Expect Rare Disease, Cancer, Immunology Drugs to Have Big Impact

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends

FDA Approved Four New Gene Therapies, Other Novel Agents in 2022

2022 Saw Continued Approvals, Uptake of Biosimilars

Specialty Pharmacy Trends to Watch in 2023

Seven Specialty Pharmacy Trends to Watch in 2023

Potential of Gene and Cell Therapies for Patients with Rare/Orphan Diseases, Ensuring Access to Treatment

PARP Inhibitors’ Data on Later Line Use in Ovarian Cancer Prompts Indication Withdrawals

AscellaHealth is One of Four Philadelphia-area companies which rank among Deloitte's 500 fastest-growing tech firms

AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

AscellaHealth - A Global Partner in Specialty Pharmacy Services for Life Sciences

Meeting the needs of rare disease patients: Improved access to specialty pharmaceuticals, gene and cell therapies

AscellaHealth Earns Merit-Based Philadelphia100 Award for Third Consecutive Year, Ranks Among Fastest Growing, Private Companies in Philadelphia Region

AscellaHealth Earns Spot on Philadelphia Business Journal “Soaring 76” List of Fastest-Growing Companies

AscellaHealth Named National Association of Specialty Pharmacy [NASP] Strategic Channel Partner of the Year

Survey Finds That Payers Are Covering Sequential Use of SMA Agents

AscellaHealth and Optime Care Collaborate with National Association of Specialty Pharmacy, Releases Podcast Series on Rare Disease Patient Journey

Deploying Next-Generation Technologies to Optimize Patient Care

AscellaHealth Family of Companies is Founding Sponsor of Inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022

AscellaHealth Named Philadelphia Business Journal PHL Inno 2022 Fire Award Honoree

AscellaHealth Achieves Favorable Ranking Among Prestigious 2022 Inc. Magazine’s 5000 Honorees: The Most Successful Companies in America For Second Consecutive Year

Terebellum, Global Healthcare and Specialty Pharmacy Solutions Company, Hosts Strategic Sessions to Architect 2023 International Pharmaceutical Partnerships and Management Training Programs

AscellaHealth and Dea Belazi honored in 2022 Fire Awards

Potential Expansion of Treatment Options for Breast Cancer

U.S. Sees First Ophthalmologic Biosimilar Launch in Crowded, High-Cost Space

Dea Belazi Named 2022 Titan 100 Award, Recognizing Philadelphia’s Top 100 CEO’s & C-level Executives

Cushing’s Syndrome

AscellaHealth Family of Companies Expands Subsidiary Terebellum’s Operations into Germany and United Kingdom, Adds New Executive Positions

Carvykti Approval Brings Second CAR-T to Multiple Myeloma Treatment

Ernst & Young Names Dea Belazi, CEO and President, AscellaHealth, Entrepreneur Of The Year 2022 Greater Philadelphia Award Finalist

AscellaHealth Awarded as One of The Financial Times’ “Americas' Fastest Growing Companies 2022” For Contribution to North and South America’s Economic Growth

AscellaHealth: Stalwarts of Specialty Pharmacy

AscellaHealth Earns Stevie Award, Named Gold Winner as Small Company of the Year for Pharmaceuticals by 2022 American Business Awards

The AscellaHealth Family of Companies Expands Executive Team Leadership for Ongoing Support of Strategic Business Initiatives and Accelerated Growth

AscellaHealth Launches Family of Companies, Expands Specialty Pharmacy Services and Capabilities to Serve Patients, Payers, Pharmaceutical Manufacturers and Providers

Success with SP Solutions

AscellaHealth’s Hub Solutions for Life Sciences Ensures Specialty Product Access and Market Entry, Optimizes Outcomes for Rare Disease Patients

Ask an Adviser: How can we cut specialty pharmacy costs?

Innovative Patient-First Approach Enhances Patient Journey, Mitigates Rising Costs for Rare Disease Drugs

AscellaHealth Hosts Specialty Pharmacy Carve-Out Webinar, Supports Self-Insured Employers and Plan Sponsors with Strategies to Manage Specialty Medical Benefit Rx Costs

With New Data, Oncopeptides Rescinds Pepaxto Withdrawal

Drug Pricing Remains Hot Topic, but Legislation Addressing It Has Stalled

Biosimilar Approvals Are Expected to Undergo Upward Trend in 2022

2022 Outlook: Notable FDA Approvals, Payer Strategies Are Specialty Trends

Optime Care Collaborates with National Association of Specialty Pharmacy, Develops Podcast on Patient Journey Across Specialty Pharmacy & Healthcare

AscellaHealth Enhances Site of Care Optimization, Awards Leading Pharmacies, Including Walmart, Preferred Status for Home Infusion Pharmacy Network

CMS Proposed NCD Will Provide Limited Medicare Coverage of Aduhelm, Other Similar Therapies

AscellaHealth Designates Preferred Status to Leading Pharmacies for Home Infusion Pharmacy Network, Enhances Site of Care Optimization

Specialty Pharmacy, Home Infusion Spaces Saw Myriad 2021 Changes

Notable 2021 Approvals Included Oncolytics, Interchangeables

Medicare Plans to Cover Aduhelm but With Certain Restrictions

AscellaHealth Awards Walmart Preferred Status for Home Infusion Pharmacy Network

Looking Forward to 2022, COVID-19 Will Continue to Impact Pharma in Myriad Ways

Innovative New Drugs, Collaborative Efforts, Digital Health Care Deals Were Among 2021 Trends

AscellaHealth Launches Expanded Website: User-Friendly Content on Global Specialty Pharmacy and Healthcare Services for Patients, Payers, Life Sciences and Providers

AscellaHealth Ranked Number 299 Fastest Growing Company in North America on the 2021 Deloitte Technology Fast 500™

AscellaHealth Forges Strategic Alliance with Optime Care

Dea Belazi’s blog on how technology advancements impact patient care

Daratumumab-RVd Demonstrates Clinical Benefits For Certain Patients With Multiple Myeloma

FDA Approves Byooviz, First Ophthalmology Biosimilar in U.S.

FDA Extends Xeljanz Safety Warnings to Other JAK Inhibitors

Key Takeaways from SIIA’s 41st Annual National Educational Conference & Expo

Partnering with the Right Specialty Pharmacy PBM

News, Trends, Challenges in Specialty Pharmacy: Rx Drug Manufacturers, Benefits Decision Makers Find Solutions in AscellaHealth Developments in Specialty Pharmacy Newsletter

Pharmacy Times Article with Dea Belazi

AscellaHealth Ranks Among Prestigious 2021 Inc. Magazine’s 5000 Honorees: One of the Country’s Fastest Growing Private Companies

AscellaHealth Presents Drug Reimbursement Strategies for 21st Century Cures - IDN & Bio Pharma Partnering Summit

Radar on Specialty Pharmacy: FDA Approval Gives Third Option to Treat Rare, Deadly Disease

AscellaHealth and Appro-Rx Partner to Provide Specialty Pharmacy Services for Improved Patient Outcomes and Lower Payer Costs

AscellaHealth Announces Partnership with Banjo Health Inc

Dea Belazi featured in RADAR on Specialty Pharmacy

Healthy Transportation Foundation Partners with AscellaHealth to Offer Discount Rx Card for Professional Truck Drivers and Families

Ensuring Specialty Pharmacy Value for Patients with Ultra-Orphan Rare Diseases

AscellaHealth Identifies Key Trends in 2021’s Evolving Pharmacy Market, Addresses Challenges

AscellaHealth and ShareSource Partner to Present 2021 Webinar

Ascella Health Releases Insights Document for Educational Webinar Series “From Evolution to Revolution: How the Rise of Specialty Pharmacy Drove a New PBM Model”

Innovative Medical Benefit Strategy Gives Plan Sponsors Greater Transparency, Insight into Specialty Drug Spend and Overall Utilization

Benefits of Partnering with a Specialty Pharmacy Benefits Manager, Account for Social Determinants of Health and Contain Costs

AscellaHealth Announces a New Specialty Medical Benefit Strategy